Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?

Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study.

Investors Business Daily

AMD's 'Golden Rabbit' GPU reportedly hits 'end of life' status — Radeon RX 7900 GRE is no longer available at any retailer

Tweakers reports that several AMD add-in board partners confirmed the upper mid-range RX 7900 GRE is now declared "end-of-life" and is no longer being produced.

Tom’s Hardware

DOJ files complaint against CVS for facilitating unlawful sale of prescription opioids

The Justice Department has unsealed a civil complaint alleging CVS Pharmacy Inc. and various subsidiaries filled unlawful prescriptions in violation of the federal Controlled Substances Act

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval

Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed.

Investors Business Daily

3 High-Yield Dividend Stocks to Secure Before Year-End

Dividend-paying stocks provide investors with consistent income in turbulent markets, especially as payouts grow over time. Therefore, investors might consider adding dividend stocks, Pfizer (PFE), United Parcel Service (UPS), and Enterprise Products Partners (EPD) before year-end. Read more….

StockNews.com

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and Robert F. Kennedy Jr. as the possible HHS lead.

Investors Business Daily

AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?

AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies?

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock performance. With a clear focus on cancer treatment innovation and a growing market presence, is the company set to lead the future of cancer care and treatment? Read more….

StockNews.com

UnitedHealth chief admits US health system ‘does not work as well as it should’

In a New York Times essay, Andrew Witty also says slain healthcare CEO Brian Thompson cared about customers

The Guardian - US

McKinsey to pay $650m to resolve US investigation into opioid crisis role

Consultancy giant agrees to two criminal counts, including for conspiring with drug manufacturers, in DoJ settlement

The Guardian - US

Mckinsey To Pay 0 Million In Purdue Pharma Settlement

McKinsey & Company agrees to pay 0 million in settlement for its role in Purdue Pharma's opioid crisis, impacting addiction and overdose prevention efforts.

Top News

McKinsey & Company agrees to pay $650 million to settle federal probe over opioids work

McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer Purdue Pharma, according to court papers filed in Virginia

The Independent UK

3 Healthcare Innovators Revolutionizing Patient Care

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading.

StockNews.com

Trump Gets In Line To 'Knock Out' Pharma Middleman; CVS Health, UnitedHealth, Cigna Keep Sliding

President-elect Trump wants to target pharmacy benefit managers. Congress is already on the case with a bill that could halve CVS Health earnings.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Analysts Predict These Will Be Next Year's Top 10 Stocks

Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025.

The Independent UK

Vifor Pharma to pay £23m to NHS after competition probe into misleading claims

The competition watchdog was investigating whether the drugs firm had been spreading misleading information on a rival’s treatment.

Investors Business Daily

Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug

Shares of Agios Pharmaceuticals collapsed Monday on an unexpected side effect related to the company's thalassemia treatment, mitapivat.

Investors Business Daily

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Assessing Biogen: Insights From 19 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months.

International Business Times UK

Worker Reveals Shocking Reason Why Women Should Check The Toilet Paper When in Walmart Washrooms

Walmart employee warns women about IV drug users cleaning needles in toilet paper rolls, sparking public health concerns and fear.

Benzinga

Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma

During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma (NASDAQ:NAMS), revealing diverse outlooks from bullish to bearish.

Benzinga

4 Analysts Assess Amylyx Pharma: What You Need To Know

During the last three months, 4 analysts shared their evaluations of Amylyx Pharma (NASDAQ:AMLX), revealing diverse outlooks from bullish to bearish.

Benzinga

Warren Buffett's Portfolio Stock Kroger Pauses Buybacks For Albertsons Merger, Narrows FY24 Outlook

Kroger pauses share buybacks for the Albertsons merger, misses Q3 sales estimates, and narrows its FY24 EPS guidance.

Investors Business Daily

The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.

Benzinga

Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket

Shares of Verint Systems Inc. (NASDAQ:VRNT) rose sharply in today's pre-market trading after the company reported a year-over-year increase in third-quarter financial results.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.